Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis

详细信息    查看全文

• 作者：Pietro Sanpaolo (1)
  Viviana Barbieri (1)
  Piernicola Pedicini (1)
  Vincenzo Fusco (1)
  
• 关键词：Early ; stage breast cancer ; Conservative therapy ; Radiation therapy ; Her ; 2/neu oncogene
• 刊名：Medical Oncology
• 出版年：2012
• 出版时间：June 2012
• 年：2012
• 卷：29
• 期：2
• 页码：459-465
• 全文大小：240KB
• 参考文献：1. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosinekinase receptor with extensive homology to EGF receptor shares chromosomal location with the neu oncogene. Science. 1985;230:1130-. external" href="http://dx.doi.org/10.1126/science.2999974">CrossRef
  2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer. Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 1987;235:177-2. external" href="http://dx.doi.org/10.1126/science.3798106">CrossRef
  3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the Her-2/neu oncogene in human breast and ovarian cancer. Science. 1989;244:707-2. external" href="http://dx.doi.org/10.1126/science.2470152">CrossRef
  4. Raudin PM, Chamness GC. The c-erbB-2 protooncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers. A review. Gene. 1995;159:19-7. external" href="http://dx.doi.org/10.1016/0378-1119(94)00866-Q">CrossRef
  5. Budzar A, Ibrahim NK, Francio D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy. Results of a randomized trial in human epidermal growth factor receptor-2 positive operable breast cancer. J Clin Oncol. 2005;23:3676-5. external" href="http://dx.doi.org/10.1200/JCO.2005.07.032">CrossRef
  6. Joensuu H, Kellolumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-0. external" href="http://dx.doi.org/10.1056/NEJMoa053028">CrossRef
  7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in Her 2-positive breast cancer. N Engl J Med. 2005;353:1659-2. external" href="http://dx.doi.org/10.1056/NEJMoa052306">CrossRef
  8. Ramond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable Her 2-positive breast cancer. N Engl J Med. 2005;353:1673-4. external" href="http://dx.doi.org/10.1056/NEJMoa052122">CrossRef
  9. Slamon DJ, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her-2/neu positive early breast cancer patients. 29th San Antonio Breast Cancer Symposium 2006; 14-7.
  10. Gonzalez-Angulo AM, Litton JK, Broglio R, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node negative tumors 1?cm or smaller. J Clin Oncol. 2009;27:5700-. external" href="http://dx.doi.org/10.1200/JCO.2009.23.2025">CrossRef
  11. Press MF, Bernstein L, Thomas PA, et al. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15(8):2894-04.
  12. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9(3):223-0.
  13. Black D, Younger J, Martei Y. Recurrence risk in T1a-b, node-negative, HER2 positive breast cancer. Breast Cancer Res Treat 2006; 100: (Abst 2037): s92.
  14. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol. 2008;26(35):5697-04. external" href="http://dx.doi.org/10.1200/JCO.2007.15.8659">CrossRef
  15. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009;27(34):5693-. external" href="http://dx.doi.org/10.1200/JCO.2009.22.0962">CrossRef
  16. ICRU. Report 62: Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda: International Commission on Radiation Units and Measurements; 1999.
  17. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer: the Her-2/neu gene and protein. Mol Cell Proteom. 2004;3:379-8. external" href="http://dx.doi.org/10.1074/mcp.R400001-MCP200">CrossRef
  18. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 1997;47:28-1. external" href="http://dx.doi.org/10.3322/canjclin.47.1.28">CrossRef
  19. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-6.
  20. McKinnel RG. Metastasis. In: McKinnel RG, Parchment RE, Perantoni AO, editors. The biological basis of cancer. New York: Cambridge University Press; 1998. p. 50-8.
  21. Charpin C, Garcia S, Bouvier C, et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patient’s overall and disease-free survival. Br J Cancer. 1997;75:1667-3. external" href="http://dx.doi.org/10.1038/bjc.1997.283">CrossRef
  22. O’Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erbB2 in lymph node-negative breast cancer. Hum Pathol. 1996;27:955-3. external" href="http://dx.doi.org/10.1016/S0046-8177(96)90224-5">CrossRef
  23. Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol. 2001;12:23-. external" href="http://dx.doi.org/10.1023/A:1011159723172">CrossRef
  24. Climent MA, Segui MA, Peirò G, et al. Prognostic value of Her-2/neu and p53 expression in node-positive breast cancer. Her-2/neu effect on adjuvant tamoxifen treatment. The Breast. 2001;10:67-7. external" href="http://dx.doi.org/10.1054/brst.2000.0225">CrossRef
  25. Sj?gren S, Ingan?s M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone or in combination with other prognostic factors. J Clin Oncol. 1998;16:462-.
  26. Swede H, Moysich KB, Winston JS, et al. Variation of the prognostic significance of Her-2 expression in breast cancer according to tumor size. Breast J. 2003;9:98-05. external" href="http://dx.doi.org/10.1046/j.1524-4741.2003.09207.x">CrossRef
  27. Smith I, Procter M, Gelber RD, et al. 2-year follows up of trastuzumab after adjuvant chemotherapy in Her-2 positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-6. external" href="http://dx.doi.org/10.1016/S0140-6736(07)60028-2">CrossRef
  28. Sidoni A, Cavaliere A, Bellezza G, et al. Breast cancer in young women: clinicopathological features and biological specificity. The Breast. 2003;12:247-0. external" href="http://dx.doi.org/10.1016/S0960-9776(03)00095-X">CrossRef
  29. Zavagno G, Meggiolaro F, Pluchinotta A, et al. Influence of age and menopausal status on pathologic and biologic features of breast cancer. The Breast. 2000;9:320-. external" href="http://dx.doi.org/10.1054/brst.1999.0147">CrossRef
  30. Daidone MG, Cordini D, Martelli G, Veneroni S. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol. 2003;45:313-5. external" href="http://dx.doi.org/10.1016/S1040-8428(02)00144-0">CrossRef
  31. Wollman R, Yahalom J, Maxy R, et al. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys. 1994;30:91-. external" href="http://dx.doi.org/10.1016/0360-3016(94)90523-1">CrossRef
  32. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 1999;5:2884-0.
  33. Liang K, Lu Y, Jin W, et al. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003;2:1113-0.
  34. She Y, Lee F, Chen J, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res. 2003;9:3773-.
  35. Pietras RJ, Poen JC, Galardo D, et al. Monoclonal antibody to Her-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999;59:1347-5.
  36. Bucholz TA, Huang EH, Berru D, et al. Her-2 positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:1337-2. external" href="http://dx.doi.org/10.1016/j.ijrobp.2004.02.018">CrossRef
  37. Harris EER, Hwang WT, Lee EA, et al. The impact of Her-2 status on local recurrence rate in women with stage I-II breast cancer treated with breast conserving therapy. Breast J. 2006;12(5):431-. external" href="http://dx.doi.org/10.1111/j.1075-122X.2006.00297.x">CrossRef
  
• 作者单位：Pietro Sanpaolo (1)
  Viviana Barbieri (1)
  Piernicola Pedicini (1)
  Vincenzo Fusco (1)
  
  1. Radiation Oncology Department, Regional Cancer Centre of Basilicata (CROB), Via Padre Pio 1, 85028, Rionero in Vulture, PZ, Italy
  

文摘

To evaluate overall survival, distant metastases-free survival and local relapse-free survival rates in a subgroup of patients affected by breast cancer expressing Her-2/neu. Data of 195 women affected by very early-stage breast cancer (pT1a-b pN0) who underwent whole breast radiotherapy after conservative surgery with or without chemotherapy and/or hormone therapy between January 2000 and December 2006 were evaluated. Chi-square test was used to compare the distribution of variables (age, tumour histology, oestrogens and progesterone receptors, tumour grading and adjuvant chemotherapy) between Her-2-positive and Her-2-negative patients. Survival rates were analysed with Kaplan–Meier curves; impact of variables on poor outcome was evaluated with Cox regression method. Median follow-up time was 63.5?months (range 13.8-13.6). Her-2/neu-positive patients (32/16.4%), compared to Her-2/neu-negative patients (163/83.6%), were younger (P?=?0.0001), were affected by ductal infiltrating carcinoma (P?=?0.039), had negative oestrogens receptors (P?=?0.0001) and were not treated with chemotherapy (P?=?0.001). Her-2-positive patients had lower overall survival (P?=?0.00001) and lower distant metastases-free survival (P?=?0.00001) compared to Her-2-negative patients, but no difference in local relapse-free survival was found between the two groups (P?=?0.28). After multivariate analysis, Her-2-positive status was a prognostic factor for overall survival (P?=?0.00001) and for distant metastases-free survival (P?=?0.0001), but not for local relapse-free survival (P?=?0.97). Her-2-positive patients have lower overall survival and distant metastases-free survival when compared to Her-2 negative patients but similar local relapse-free survival rates. These patients could be treated with conservative surgery, if feasible, but should receive more aggressive and tailored systemic adjuvant therapies.